Patents by Inventor Neeraj Kohli

Neeraj Kohli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140234314
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • Publication number: 20140127207
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: January 3, 2014
    Publication date: May 8, 2014
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • Patent number: 8623196
    Abstract: The present invention provides compositions, devices and methods for detecting esterase activity. The present invention also provides devices and methods of detecting esterase inhibitors, for example, organophosphates. In particular, the present invention provides a biosensor comprising Neuropathy Target Esterase (NTE) polypeptides. Further, the present invention relates to medicine, industrial chemistry, agriculture, and homeland security.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: January 7, 2014
    Assignees: Michigan State University, The Regents of the University of Michigan
    Inventors: Neeraj Kohli, Devesh Srivastava, Rudy J. Richardson, Jun Sun, Ilsoon Lee, Robert M. Worden
  • Publication number: 20130236459
    Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: February 27, 2013
    Publication date: September 12, 2013
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Patent number: 8476409
    Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: July 2, 2013
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
  • Patent number: 8435773
    Abstract: A chemical composite useful for preparing a bioelectronic device includes a biologically active compound, such as an enzyme, that is bound directly or indirectly to a polyelectrolyte, which can be reversibly coupled to a chemically treated electrically conductive substrate by electrostatic forces to provide biomimetic sensors, catalyst systems, and other devices having an electrode that can be regenerated and reused. Required or desired cofactors, mediators or the like may be incorporated into the devices, typically by bonding them to the treated substrate and/or the polyelectrolyte.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: May 7, 2013
    Assignee: Board of Trustees of Michigan State University
    Inventors: Robert M. Worden, Robert Y. Ofoli, Brian L. Hassler, Neeraj Kohli, Ilsoon Lee
  • Publication number: 20120269812
    Abstract: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 25, 2012
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
  • Publication number: 20120244163
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 27, 2012
    Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
  • Publication number: 20120160708
    Abstract: The present invention provides compositions, devices and methods for detecting esterase activity. The present invention also provides devices and methods of detecting esterase inhibitors, for example, organophosphates. In particular, the present invention provides a biosensor comprising Neuropathy Target Esterase (NTE) polypeptides. Further, the present invention relates to medicine, industrial chemistry, agriculture, and homeland security.
    Type: Application
    Filed: May 15, 2008
    Publication date: June 28, 2012
    Inventors: Neeraj Kohli, Devesh Srivastava, Rudy J. Richardson, Jun Sun, Ilsoon Lee, Robert M. Worden
  • Publication number: 20110287002
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: May 4, 2011
    Publication date: November 24, 2011
    Applicant: ADIMAB, LLC
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND
  • Publication number: 20090130698
    Abstract: A chemical composite useful for preparing a bioelectronic device includes a biologically active compound, such as an enzyme, that is bound directly or indirectly to a polyelectrolye, which can be reversibly coupled to a chemically treated electrically conductive substrate by electrostatic forces to provide biomimetic sensors, catalyst systems, and other devices having an electrode that can be regenerated and reused. Required or desired cofactors, mediators or the like may be incorporated into the devices, typically by bonding them to the treated substrate and/or the polyelectrolyte.
    Type: Application
    Filed: May 10, 2006
    Publication date: May 21, 2009
    Inventors: Robert M. Worden, Robert Y. Ofoli, Brian L. Hassler, Neeraj Kohli, Ilsoon Lee